Lazard Welcomes Michele Colocci as Vice Chairman, Investment Banking and Managing Director, Healthcare
09 Mayo 2024 - 2:00AM
Business Wire
Lazard, Inc. (NYSE: LAZ) today announced Michele Colocci is
joining the firm on 3rd June 2024 as Vice Chairman, Investment
Banking and Managing Director, Healthcare. Based in London, Mr.
Colocci’s appointment accelerates the growth of Lazard’s
best-in-class global healthcare franchise, led by David Gluckman,
and further reinforces its leading position in Europe, which is
headed by Jean-Louis Girodolle and Cyrus Kapadia.
Mr. Colocci is a globally recognized advisor with a particular
focus on healthcare, having worked with biopharma clients across
EMEA, the US, and Japan. With three decades of investment banking
expertise, he most recently served as Managing Director and
Chairman of M&A at Morgan Stanley, where among other previous
leadership roles, he also served as Global Co-Head of Healthcare
Investment Banking and as Deputy Head of European Investment
Banking. He previously also held the role of Global Co-Head of
Healthcare Investment Banking at JPMorgan. Michele began his career
as a management consultant at Bain & Co. and is a graduate of
Williams College and Harvard Business School.
“Michele’s experience as a trusted advisor to clients will be
tremendously valuable as we continue to invest in our significant
European business,” said Peter R. Orszag, Chief Executive Officer
of Lazard. “His expertise will help advance the expansion of our
preeminent healthcare business, and we are thrilled to welcome him
to Lazard.”
“Lazard is at an exciting inflection point in its growth plans,
and I am honored to be joining the firm at this time,” said Michele
Colocci. “Advisors continually strive to differentiate themselves
for the clarity, independence and relevance of their advice to
clients as they seek to manage risk, innovate and grow — Lazard has
long focused its franchise around these elements and I very much
look forward to joining that effort.”
Lazard’s leading EMEA business represented close to 40% of total
financial advisory revenues as of 31st March 2024, reflecting the
strength of the team and depth of relationships built over close to
two centuries. Lazard is also one of the leading advisors in
healthcare, with recently announced and closed transactions
including: Vertex’s $4.9 billion acquisition of Alpine Immune
Sciences; Galderma’s IPO, CymaBay Therapeutic’s $4.3 billion
acquisition by Gilead; Sanofi’s $2.4 billion acquisition of
Inhibrx; ImmunoGen’s $10.1 billion acquisition by AbbVie; Abcam’s
$5.7 billion sale to Danaher; Biogen’s $7.3 billion acquisition of
Reata Pharmaceuticals; and CVS Health's $10.6 billion acquisition
of Oak Street Health.
About Lazard
Founded in 1848, Lazard is one of the world's preeminent
financial advisory and asset management firms, with operations in
North and South America, Europe, the Middle East, Asia, and
Australia. Lazard provides advice on mergers and acquisitions,
capital markets and capital solutions, restructuring and liability
management, geopolitics, and other strategic matters, as well as
asset management and investment solutions to institutions,
corporations, governments, partnerships, family offices, and high
net worth individuals. For more information, please visit
www.lazard.com.
LAZ-FAPE
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240509961714/en/
Media Relations
Poppy Trowbridge, +44 207 187 2065
poppy.trowbridge@lazard.com
Flore Larger, +33 1 44 13 01 30 flore.larger@lazard.com
Investor Relations
Alexandra Deignan, +1 212 632 6886
alexandra.deignan@lazard.com
Lazard (NYSE:LAZ)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lazard (NYSE:LAZ)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024